Drug Trial Radar · NCT01478178
Safety Study of VAL-083 in Patients With Recurrent Malignant Glioma
Last checked: Nov 19, 2026Latest source record: Aug 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
55
Actual
Start
Oct 2011
Primary completion
Dec 2015
Study completion Oct 2016
Sponsor
- Lead sponsor
- Kintara Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 23, 2011
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this Phase 1/2, open-label, single-arm study is to determine the safety and the maximal tolerated dose (MTD) of VAL-083 in patients with recurrent malignant glioma. Pharmacokinetic (PK) properties will be explored and tumor responses to treatment will be evaluated.
Conditions
- Glioma
- Glioblastoma
- Glioblastoma Multiforme
- GBM
- Brain Cancer
Interventions
VAL-083 (Dianhydrogalactitol)Drug
VAL-083 given by intravenous infusion with a starting dose of 1.5 mg/m2 IV. Escalating doses to be administered in sequential dose cohorts.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Determination of maximum tolerated dose (MTD)Time frame: Study Day 35
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
University of California, San Francisco, Division of Neuro-Oncology
San Francisco, California
Sarah Cannon Research Institute
Denver, Colorado
Florida Cancer Specialists
Sarasota, Florida
Mayo Clinic
Rochester, Minnesota
Sarah Cannon Research Institute
Nashville, Tennessee
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.